Aggregated price index with volume information
Summary:
- Pot stocks up 2.1% on average while median return up 2.0% in a day
- Pot stocks up 3.0% on average while median return up 2.3% in a week
- Pot stocks up 8.3% on average while median return up 4.5% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $SNDL 17.3%, $TLRY 8.3%, $OGI 7.2%, $TOKE 4.8%
- 1M losers are : Losers for past month are $MJ -0.3%
- 1W winners are : Winners for past week are $SNDL 8.2%, $TOKE 5.7%, $MJ 2.9%, $CNBS 2.4%
- 1W losers are : Losers for past week are $OGI -1.2%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 41.2%, for the past 3 months is 44.7%
In the past month for a 5 days rolling window, the highest corrrelation is 62.8%, the lowest correlation is 15.6%, the latest correlation is 52.9%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 91.1% between CNBS and YOLO
The lowest correlation is -19.5% between SNDL and THCX
TORONTO, July 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 second quarter earnings conference call on Thursday, August 8, 2024 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/eve
Update: Organigram Loses 4.7% as it Completes a Partial Third-Tranche Investment of US$1 Million in Phylos
Tilray's (TLRY) product innovation, spanning medical cannabis formats, THC-infused beverages and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally.
Organigram Completes Partial Third Tranche Investment of US$1 Million in Phylos
Tilray's Solução Oral THC10:CBD10 Medical Cannabis Extract is Now Approved for Medical Use in PortugalCANTANHEDE, Portugal, July 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced another milestone achievement in medical cannabis in Europe. Following the successful approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portug
TORONTO, July 24, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has completed an early partial funding of its final third tranche investment into Phylos Bioscience Inc. ("Phylos"), a U.S. cannabis genetics company and provider of production ready seeds, with the remaining portion of the final tranche to be funded upon completion of the newly expanded final milestone.
Tilray Brands, Inc. (TLRY) closed at $1.89 in the latest trading session, marking a -1.56% move from the prior day.
North American cannabis firms, facing prohibitive laws, an overcrowded market and a deeply entrenched illicit sector at home are ramping up investments in Germany after the country partly legalized marijuana use. Germany, the largest medical cannabis market in Europe, decriminalized cannabis possession and small-scale home cultivation in April, making it easier for doctors to prescribe it. But only a few local companies are licensed to grow pot, and U.S. and Canadian firms are looking to captu...
TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at its Annual Meeting of Shareholders (the “Meeting”) reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company’s independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete re
Tilray Up 2.8% In US Premarket As Says Received First New Cannabis Cultivation License in Germany Under New Regulations